-
Blog BLOG
-
Product Center BRAND DYNAMICS
-
Investor INVESTOR RELATIONS
-
Contact Us CONTACT
-
Supervise SUPERVISION
HealthGen and Bayer have reached an exclusive licensing agreement for a small molecule inhibitor, further strengthening their innovative drug strategy and expanding their respiratory disease pipeline.
Published Time:
2024-03-21
On March 20, 2024, HealthGen Biotech Group and Bayer signed an exclusive license agreement for the development, commercialization, and production of a small molecule inhibitor in China. This marks HealthGen's first introduction of an innovative respiratory drug pipeline from a leading global multinational company.
The small molecule compound involved is an innovative oral medication for chronic obstructive pulmonary disease ( COPD). It works by inhibiting prolyl endopeptidase (PREP) activity, effectively preventing the production of COPD inflammatory mediators. This unique mechanism of action is expected to provide significant benefits to COPD patients and may positively impact overall disease progression.
Public research shows that, COPD is a global health problem. In China, in particular, COPD has become a public health issue, affecting the quality of life for hundreds of millions of people. As one of the key diseases to be prevented and controlled in the "Healthy China 2030" action plan, the situation regarding COPD prevention and control is extremely severe. In recent years, many representatives and committee members have continuously focused on the issue of COPD prevention and control at the National People's Congress. At this year's National People's Congress, the topic of exploring an appropriate COPD prevention and control model for China's national conditions has once again received attention from many national people's congress representatives and CPPCC members, with representatives calling for the inclusion of COPD prevention and control in national basic public health service programs.
The results of the "China Adult Lung Health Study" show that there are approximately 100 million COPD patients in China, with a prevalence of 8.6% among people over 20 years old and a prevalence as high as 13.7% among people over 40 years old. COPD is now the third most common chronic non-communicable disease. Despite continuous advancements in treatment methods, COPD still has the characteristics of high incidence, high disability rate, high mortality rate, and low awareness, low diagnosis rate, and low control rate ("three highs and three lows"). In China, in particular, the prevalence and burden of COPD are exceptionally heavy, making effective treatment options urgently needed.
Currently, globally, the choice of oral medications for COPD is very limited. Domestic treatments for chronic obstructive pulmonary disease still mainly rely on bronchodilators and corticosteroids, lacking oral anti-inflammatory drugs. This licensed compound is an innovative oral drug developed by Bayer and has successfully completed Phase I clinical trials in Europe.
Based on its good response and progress in research, this drug may become an important therapeutic breakthrough, bringing to China new treatment strategies for COPD patients.
As a leading innovative pharmaceutical company in the field of inhalation preparations, HealthGen has always regarded the inhalation preparation sector as one of its strategic priorities. In addition to strengthening its own research and development, HealthGen has also introduced multiple innovative drugs, continuously expanding the company's Big Pharma-level product pipeline. With the exclusive license from Bayer, HealthGen has reached three important strategic collaborations in the respiratory field this year.
At the end of January 2024, HealthGen successively announced two major strategic collaborations for drugs mainly used to treat asthma and chronic obstructive pulmonary disease and other respiratory diseases, including a strategic collaboration with Quansin Bio on the TSLP monoclonal antibody QX008N and a collaboration with Boan Bio on the exclusive rights in China for the long-acting anti-IL-4Rα monoclonal antibody BA2101 injection. These three collaborations have achieved expansion from injections to oral medications, further enriching HealthGen's layout of R&D pipelines and product varieties in the respiratory field.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Sorry,当前栏目暂无内容!
您可以查看其他栏目或返回 首页
Sorry,The current column has no content!
You can view other columns or return Home